NEW YORK (GenomeWeb News) – Atossa Genetics today said that its revenues in the first quarter increased more than three-fold, driven by the national launch of its breast cancer diagnostic test.

The Seattle-based firm recorded $182,670 in revenues, compared to $54,713 in the first quarter of 2012. Diagnostic testing service revenues were up 221 percent to $169,230 from $52,713 a year ago, while product sales rose more than six-fold to $13,440 from $2,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.